Homepage>Company>Media>Pharma News>2016>Boston Biomedical Initiates CanStem303C: A Global Phase III Study Investigating Cancer Stemness Inhibitor Napabucasin in Patients With Pretreated Advanced Colorectal Cancer
Boston Biomedical Initiates CanStem303C: A Global Phase III Study Investigating Cancer Stemness Inhibitor Napabucasin in Patients With Pretreated Advanced Colorectal Cancer